June 2023 FDA Recall Tizanidine by Amerisource Health Services Llc
D-0892-2023 - Failed Dissolution Specifications

This Class II drug recall was voluntarily initiated by Amerisource Health Services Llc on June 23, 2023 for the product Tizanidine. The FDA reported the reason for recall as failed dissolution specifications. The product was distributed Nationwide and the recall is currently terminated.

Recall Number: D-0892-2023

Reason for Recall
Failed Dissolution Specifications: this repackaged product was recalled by the manufacturer, Dr. Reddy's Laboratories, Inc., due to out of specification results for dissolution.
Initiated
06-23-2023
Reported
07-12-2023
Quantity
4,971 cartons

Recall Profile & Regulatory Data

Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Amerisource Health Services LLC
Nationwide in the USA
Tizanidine Tablets, USP, 4 mg, 100 Tablets (10 tablets x 10 unit dose blister packs) per carton, Rx Only, Packaged and Distributed by: American Health Packaging, Columbus, Ohio 43217, NDC 68084-645-01 (carton), barcode (01) 003 68084 645 11 2.

Batch or Lot Expiration Information

Lot# Lot 1004835, Exp 7/31/2023